MedPath

Multi-Institutional Collaborative Study for Estimating the Persistence of Treatment Free Remission in Chronic Myeloid Leukemia after Stopping Tyrosine Kinase Inhibitor in Japa

Not Applicable
Recruiting
Conditions
CML (chronic myeloid leukemia)
Registration Number
JPRN-UMIN000037535
Lead Sponsor
THE JAPANESE SOCIETY OF HEMATOLOGY
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
1200
Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients who can not provide clinical information and data before and after stopping TKI or after re-treatment by TKI 2) Other, patients whom the investigator considers to be unsuitable for participation in the study.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
TFR rate at 5-years after stopping TKI
Secondary Outcome Measures
NameTimeMethod
TFR rate at 10-years after stopping TKI Estimated Treatment Free Survival (TFS) or Progression Free Survival (PFS) to AP or BC after stopping TKI Cumulative Re-MMR rate after retreatment with TKI in patients who lost TFR
© Copyright 2025. All Rights Reserved by MedPath